Yago Nieto

Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yago Nieto is a Professor at The University of Texas MD Anderson Cancer Center in the United States. His research primarily focuses on high-dose chemotherapy, pharmacokinetics in chemotherapy protocols, and the application of engineered natural killer cells in the treatment of refractory lymphomas and multiple myeloma. Recent publications highlight advancements in treatments for relapsed germ cell tumors and the efficacy of various combinations of chemotherapy regimens.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (10)

John Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jason R. Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Borje Andersson

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Michael Spinner

Clinical Assistant Professor of Medicine (Hematology/Oncology)

University of California, San Francisco

UNITED STATES

View details

Qaiser Bashir

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rafet Basar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Fevzi Yalniz

University of Kentucky

UNITED STATES

View details

Ken Chen

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jeremy Ramdial

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yago Nieto

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience

Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Harnessing engineered NK cells for refractory CD30+ lymphoma

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma

Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts

Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma

Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant

Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.

CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.

Gene expression profiling predicts relapse‐free and overall survival in newly diagnosed myeloma patients treated with novel therapies

Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Collaborators (10)

John Lin

Jason R. Westin

Borje Andersson

Michael Spinner

Qaiser Bashir

Rafet Basar

Robert Orlowski

Fevzi Yalniz

Ken Chen

Jeremy Ramdial

Make your next move.